Analysts Set Aspen Aerogels, Inc. (NYSE:ASPN) Target Price at $29.70

Aspen Aerogels, Inc. (NYSE:ASPN) has been given a consensus recommendation of “Buy” by the ten ratings firms that are presently covering the stock, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $29.70.

A number of brokerages recently weighed in on ASPN. B. Riley upgraded shares of Aspen Aerogels to a “strong-buy” rating in a report on Tuesday, June 25th. Roth Mkm reaffirmed a “buy” rating and set a $36.00 price target on shares of Aspen Aerogels in a report on Wednesday, August 21st. TD Cowen lifted their price objective on Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, August 20th. Barclays started coverage on shares of Aspen Aerogels in a research note on Tuesday, August 6th. They set an “overweight” rating and a $27.00 target price on the stock. Finally, Benchmark reiterated a “buy” rating and issued a $14.00 price target on shares of Aspen Aerogels in a research note on Thursday, August 8th.

Aspen Aerogels Stock Down 3.8 %

Shares of NYSE:ASPN opened at $21.60 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.82 and a debt-to-equity ratio of 0.23. The stock has a fifty day simple moving average of $26.00 and a two-hundred day simple moving average of $24.35. Aspen Aerogels has a 12-month low of $6.62 and a 12-month high of $33.15. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -49.08 and a beta of 2.16.

Aspen Aerogels (NYSE:ASPN) last announced its quarterly earnings results on Wednesday, August 7th. The construction company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The company had revenue of $117.80 million for the quarter, compared to analysts’ expectations of $101.99 million. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. Aspen Aerogels’s revenue was up 144.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.22) EPS. On average, research analysts anticipate that Aspen Aerogels will post 0.21 earnings per share for the current fiscal year.

Insider Buying and Selling at Aspen Aerogels

In other news, CFO Ricardo C. Rodriguez sold 32,465 shares of Aspen Aerogels stock in a transaction on Monday, August 26th. The shares were sold at an average price of $30.14, for a total transaction of $978,495.10. Following the transaction, the chief financial officer now owns 20,790 shares in the company, valued at $626,610.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the sale, the chief executive officer now owns 483,640 shares in the company, valued at approximately $14,523,709.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the transaction, the chief financial officer now owns 20,790 shares of the company’s stock, valued at approximately $626,610.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Banque Cantonale Vaudoise raised its holdings in Aspen Aerogels by 37.5% during the first quarter. Banque Cantonale Vaudoise now owns 4,593 shares of the construction company’s stock valued at $81,000 after acquiring an additional 1,252 shares during the period. Harbour Capital Advisors LLC bought a new stake in Aspen Aerogels during the 1st quarter valued at approximately $404,000. Bridgewater Advisors Inc. purchased a new position in Aspen Aerogels in the 1st quarter worth approximately $750,000. BNP Paribas Financial Markets boosted its stake in Aspen Aerogels by 85.2% in the 1st quarter. BNP Paribas Financial Markets now owns 25,706 shares of the construction company’s stock worth $452,000 after purchasing an additional 11,823 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Aspen Aerogels during the 1st quarter valued at approximately $1,181,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.